FDA grants De Novo authorization to Brixton Biosciences’ ReneuRx nerve-selective pain device
FDA records show a De Novo grant for Brixton Biosciences’ ReneuRx, also known as Neural Ice, a nerve-selective technology developed as a drug-free injectable approach to longer-lasting knee osteoarthritis pain control.